Literature DB >> 25582444

Multiple sclerosis in 2014. Progress in MS--classification, mechanisms and treatment.

Jiwon Oh1, Paul W O'Connor1.   

Abstract

Scientific progress in multiple sclerosis (MS) research spanned a number of areas in 2014, including therapeutics, disease classification, risk management, and disease mechanisms. Advances were particularly notable in the field of progressive MS. Altogether, the findings move us one step closer to a better understanding of this complex disease.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25582444     DOI： 10.1038/nrneurol.2014.259

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


  9 in total

Review 1.  The radiologically isolated syndrome: look (again) before you treat.

Authors:  Rebecca Spain; Dennis Bourdette
Journal:  Curr Neurol Neurosci Rep       Date:  2011-10       Impact factor: 5.081

2.  In vivo evidence of glutamate toxicity in multiple sclerosis.

Authors:  Christina J Azevedo; John Kornak; Philip Chu; Mehul Sampat; Darin T Okuda; Bruce A Cree; Sarah J Nelson; Stephen L Hauser; Daniel Pelletier
Journal:  Ann Neurol       Date:  2014-07-09       Impact factor: 10.422

3.  Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis.

Authors:  Luisa M Villar; Bonaventura Casanova; Nadia Ouamara; Manuel Comabella; Farzaneh Jalili; David Leppert; Clara de Andrés; Guillermo Izquierdo; Rafael Arroyo; Timuçin Avşar; Sergey V Lapin; Trina Johnson; Xavier Montalbán; Oscar Fernández; Roberto Álvarez-Lafuente; Donna Masterman; María I García-Sánchez; Francisco Coret; Aksel Siva; Evgeniy Evdoshenko; José C Álvarez-Cermeño; Amit Bar-Or
Journal:  Ann Neurol       Date:  2014-07-02       Impact factor: 10.422

4.  Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.

Authors:  Peter A Calabresi; Bernd C Kieseier; Douglas L Arnold; Laura J Balcer; Alexey Boyko; Jean Pelletier; Shifang Liu; Ying Zhu; Ali Seddighzadeh; Serena Hung; Aaron Deykin
Journal:  Lancet Neurol       Date:  2014-04-30       Impact factor: 44.182

5.  Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.

Authors:  Jeremy Chataway; Nadine Schuerer; Ali Alsanousi; Dennis Chan; David MacManus; Kelvin Hunter; Val Anderson; Charles R M Bangham; Shona Clegg; Casper Nielsen; Nick C Fox; David Wilkie; Jennifer M Nicholas; Virginia L Calder; John Greenwood; Chris Frost; Richard Nicholas
Journal:  Lancet       Date:  2014-03-19       Impact factor: 79.321

6.  Spinal cord gray matter atrophy correlates with multiple sclerosis disability.

Authors:  Regina Schlaeger; Nico Papinutto; Valentina Panara; Carolyn Bevan; Iryna V Lobach; Monica Bucci; Eduardo Caverzasi; Jeffrey M Gelfand; Ari J Green; Kesshi M Jordan; William A Stern; H-Christian von Büdingen; Emmanuelle Waubant; Alyssa H Zhu; Douglas S Goodin; Bruce A C Cree; Stephen L Hauser; Roland G Henry
Journal:  Ann Neurol       Date:  2014-08-21       Impact factor: 10.422

7.  Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Tatiana Plavina; Meena Subramanyam; Gary Bloomgren; Sandra Richman; Amy Pace; Sophia Lee; Brian Schlain; Denise Campagnolo; Shibeshih Belachew; Barry Ticho
Journal:  Ann Neurol       Date:  2014-10-24       Impact factor: 10.422

8.  Radiologically isolated syndrome: 5-year risk for an initial clinical event.

Authors:  Darin T Okuda; Aksel Siva; Orhun Kantarci; Matilde Inglese; Ilana Katz; Melih Tutuncu; B Mark Keegan; Stacy Donlon; Le H Hua; Angela Vidal-Jordana; Xavier Montalban; Alex Rovira; Mar Tintoré; Maria Pia Amato; Bruno Brochet; Jérôme de Seze; David Brassat; Patrick Vermersch; Nicola De Stefano; Maria Pia Sormani; Daniel Pelletier; Christine Lebrun
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

9.  Defining the clinical course of multiple sclerosis: the 2013 revisions.

Authors:  Fred D Lublin; Stephen C Reingold; Jeffrey A Cohen; Gary R Cutter; Per Soelberg Sørensen; Alan J Thompson; Jerry S Wolinsky; Laura J Balcer; Brenda Banwell; Frederik Barkhof; Bruce Bebo; Peter A Calabresi; Michel Clanet; Giancarlo Comi; Robert J Fox; Mark S Freedman; Andrew D Goodman; Matilde Inglese; Ludwig Kappos; Bernd C Kieseier; John A Lincoln; Catherine Lubetzki; Aaron E Miller; Xavier Montalban; Paul W O'Connor; John Petkau; Carlo Pozzilli; Richard A Rudick; Maria Pia Sormani; Olaf Stüve; Emmanuelle Waubant; Chris H Polman
Journal:  Neurology       Date:  2014-05-28       Impact factor: 9.910
  9 in total
  2 in total

1.  Electroacupuncture Promotes Remyelination after Cuprizone Treatment by Enhancing Myelin Debris Clearance.

Authors:  Keying Zhu; Jingxian Sun; Zheng Kang; Zaofeng Zou; Gencheng Wu; Jun Wang
Journal:  Front Neurosci       Date:  2017-01-10       Impact factor: 4.677

2.  Tyrosine Kinase Receptors Axl and MerTK Mediate the Beneficial Effect of Electroacupuncture in a Cuprizone-Induced Demyelinating Model.

Authors:  Zaofeng Zou; Jingxian Sun; Zheng Kang; Yumeng Wang; Hui Zhao; Keying Zhu; Jun Wang
Journal:  Evid Based Complement Alternat Med       Date:  2020-07-04       Impact factor: 2.629
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.